Wednesday, February 8, 2023
Market-Reporter
  • Home
  • Markets
    • U.S. Markets
    • Canada
    • Europe & Middle East
    • Emerging Markets
    • Asia
    • Latin America
  • Investing
    • Stocks
    • IPOs
    • Mutual Funds
    • ETFs
    • Bonds
    • Commodities
    • Currencies
    • Cryptocurrencies
  • Economy & Politics
    • Personal Finance
    • Spending & Saving
    • Retirement
    • Real Estate
No Result
View All Result
  • Home
  • Markets
    • U.S. Markets
    • Canada
    • Europe & Middle East
    • Emerging Markets
    • Asia
    • Latin America
  • Investing
    • Stocks
    • IPOs
    • Mutual Funds
    • ETFs
    • Bonds
    • Commodities
    • Currencies
    • Cryptocurrencies
  • Economy & Politics
    • Personal Finance
    • Spending & Saving
    • Retirement
    • Real Estate
No Result
View All Result
Market-Reporter
No Result
View All Result
Home IPOs

Another four IPOs complete busy week as biotech raise continues to match 2020’s record pace – Endpoints News

MtR by MtR
June 18, 2021
in IPOs
0


Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

One of the busiest IPO weeks of the year has capped off with an­oth­er four biotechs ex­pect­ed to make their pub­lic de­buts Fri­day.

Af­ter Lyell, Verve and Mol­e­c­u­lar Part­ners all priced ear­li­er in the week, ATAI Life Sci­ences, Cen­tu­ry Ther­a­peu­tics, Am­brx Bio­phar­ma and Cyteir Ther­a­peu­tics each fol­lowed suit with nine-fig­ure rais­es af­ter mar­ket close Thurs­day. All that ef­fort has dri­ven the com­bined biotech IPO raise close to $9 bil­lion, per the End­points News tal­ly.

With the end of the sec­ond quar­ter rapid­ly ap­proach­ing, the in­dus­try is well on its way to eclips­ing 2020’s record IPO fig­ures. Last year saw a $16.5 bil­lion com­bined raise from 91 biotechs, ac­cord­ing to Nas­daq, where 2021’s sum thus far comes from 53 new­ly pub­lic com­pa­nies.

ATAI led Fri­day’s group, tal­ly­ing a $225 mil­lion raise at $15 per share. Cen­tu­ry al­so hit the $200 mil­lion mark, rais­ing $211 mil­lion at $20 per share. Cyteir and Am­brx fol­lowed up with to­tals of $133 mil­lion and $126 mil­lion, re­spec­tive­ly, each launch­ing their stock at $18.

‘Be­liev­ing in mag­ic,’ Thiel-backed ATAI jumps to Nas­daq

Pe­ter Thiel

Backed by bil­lion­aire Pe­ter Thiel, ATAI has com­plet­ed the next step in its jour­ney as it con­tin­ues its unique mis­sion of wrap­ping sev­er­al psy­che­del­ic biotechs un­der one cor­po­rate um­brel­la.

The IPO fol­lows two nine-fig­ure pri­vate rais­es, with a $125 mil­lion Se­ries C last No­vem­ber and a $157 mil­lion Se­ries D in March. CEO Flo­ri­an Brand told End­points News at the time that their psy­che­del­ic strat­e­gy proved es­sen­tial in dri­ving that heavy in­vestor in­ter­est, and that os­ten­si­bly con­tin­ued in­to ATAI’s Nas­daq leap.

Hav­ing fin­ished its IPO prep, we can now glean some more in­for­ma­tion out of ATAI’s pub­lic plans thanks to an up­dat­ed S-1 fil­ing. The biotech list­ed sev­en of their 14 port­fo­lio com­pa­nies to­ward which IPO funds will be di­rect­ed, with Per­cep­tion and Recog­ni­fy lead­ing the way. Per­cep­tion had been one of ATAI’s ear­li­est ac­qui­si­tions, while Recog­ni­fy joined the fold this past Jan­u­ary.

Per­cep­tion’s cash will be used to launch and com­plete a Phase II study for a pro­gram in treat­ment re­sis­tant de­pres­sion, while Recog­ni­fy is look­ing to fin­ish a Phase IIa tri­al for their can­di­date they say can mod­u­late the cholin­er­gic, NM­DA and GA­BA type B re­cep­tor sys­tems.

The oth­er com­pa­nies specif­i­cal­ly slat­ed for funds are De­meRx, GA­BA Ther­a­peu­tics, Neu­ronasal, Kures and Viridia. But ATAI isn’t stop­ping there, sav­ing a mas­sive amount for oth­er play­ers in their port­fo­lio and set­ting aside $75 to $85 mil­lion for an­oth­er po­ten­tial ac­qui­si­tion.

ATAI will trade un­der the tick­er $ATAI. Founder Chris­t­ian Anger­may­er, who con­trols the largest stake in ATAI at 19.1% post-of­fer­ing, tweet­ed his ap­par­ent plea­sure at the news ear­ly Fri­day.

Be hap­py. Live your dreams. Be­lieve in mag­ic. ???

— Chris­t­ian Anger­may­er (@C_Anger­may­er) June 18, 2021

Cell ther­a­py play­er Cen­tu­ry con­tin­ues its hot streak

Look­ing to cap­i­tal­ize on the mo­men­tum in an­oth­er hot mar­ket — al­lo­gene­ic cell ther­a­py — CEO La­lo Flo­res is steer­ing Cen­tu­ry to Nas­daq.

La­lo Flo­res

The IPO con­tin­ues a big year for Flo­res, who nailed down a $160 mil­lion raise back in March to scale their iP­SC plat­form for CAR-T and CAR-NK ef­forts. Cen­tu­ry is tak­ing what they see as a dif­fer­ent ap­proach to the tech­nol­o­gy, how­ev­er, opt­ing for in­duced pluripo­tent stem cells rather than donor cells.

Cen­tu­ry’s lead pro­gram, a CD19 CAR-NK that they hope to steer in­to a hu­man tri­al by 2022, is ex­pect­ed to see a $50 mil­lion wind­fall from the IPO. Three oth­er pro­grams will get a com­bined $110 mil­lion in funds, Cen­tu­ry said in its S-1 ear­li­er this week.

The tri­umvi­rate of those pre­clin­i­cal pro­grams tar­get­ing CD133 and EGFR, CD19 and CD79b, as well as an­oth­er mul­ti­spe­cif­ic can­di­date. If every­thing goes as planned, Cen­tu­ry will com­plete its slate of INDs by the end of 2024. An­oth­er $35 mil­lion is slat­ed to boost the biotech’s man­u­fac­tur­ing ca­pa­bil­i­ties.

Cen­tu­ry has some big play­ers as its top in­vestors, who will each see hefty wind­falls with the IPO raise. Ver­sant is the biotech’s biggest share­hold­er with a 24.7% post-of­fer­ing stake, while Bay­er will con­trol 21.8% of shares once the IPO is com­plet­ed. Fu­ji­film’s cell man­u­fac­tur­ing sub­sidiary al­so owns 12.7% of Cen­tu­ry.

Once it rings in the IPO on Fri­day, Cen­tu­ry will trade un­der the tick­er $IP­SC.

Cyteir hits the bulls­eye in IPO raise

Cyteir’s pub­lic leap comes af­ter a Se­ries C round in Feb­ru­ary that saw the biotech pull in $80 mil­lion.

They’ve in­vest­ed heav­i­ly in their lead pro­gram, an oral in­hibitor of RAD51-me­di­at­ed DNA re­pair, and the biotech is aim­ing to po­ten­tial­ly com­plete a Phase II tri­al as a monother­a­py with $85 mil­lion of the $133 mil­lion IPO. Tar­get­ing RAD51, the can­di­date hits at a crit­i­cal en­zyme in dou­ble-strand­ed DNA re­pair, as Cyteir re­search­es the con­cept of syn­thet­ic lethal­i­ty.

Markus Ren­schler

The biotech hopes the phe­nom­e­non can in­hib­it the DNA dam­age re­pair can­cer cells need to sur­vive and grow, CEO Markus Ren­schler told End­points in Feb­ru­ary.

Be­hind this pro­gram is an­oth­er RAD51 can­di­date, but is still in the pre­clin­i­cal stage. Here, Cyteir will fun­nel $22 mil­lion of its IPO cash, and save the rest for oth­er gen­er­al R&D and cor­po­rate pur­pos­es.

Cyteir has some big back­ers be­hind the IPO, with No­vo hold­ings top­ping the charts at a 13.2% stake af­ter the of­fer­ing. Jan­willem Nae­sens’ Droia Ven­tures comes in sec­ond with a 9.5% stake, match­ing the shares owned by Ven­rock. And RA Cap­i­tal and Cel­gene/Bris­tol My­ers Squibb each own sig­nif­i­cant stakes, at 5.8% and 5.1%, re­spec­tive­ly.

Oth­er ma­jor stock­hold­ers in­clude Os­age Uni­ver­si­ty Part­ners II at 7.2% and Light­stone Ven­tures at 7.1%. Cyteir will trade un­der the tick­er $CYT.

Sec­ond time’s the charm for re-en­er­gized Am­brx

Am­brx’s sec­ond at­tempt to go pub­lic has end­ed in suc­cess, fol­low­ing a 2014 ef­fort that was with­drawn.

Af­ter sell­ing it­self to a syn­di­cate of Chi­nese in­vestors and phar­ma com­pa­nies, Am­brx laid low un­til a $200 mil­lion crossover raise last No­vem­ber helped com­plete its piv­ot to Chi­na. They’ve lined up part­ner­ships with Mer­ck, Bris­tol My­ers Squibb and Eli Lil­ly over the years, and signed dis­cov­ery deals with BeiGene, Suzhou-based Mab­Space and Shang­hai-based NovoCodex, among oth­ers.

Am­brx moved its first in-house drug in­to the clin­ic, a HER2-tar­get­ing an­ti­body-drug con­ju­gate, and much of the IPO’s cash will fo­cus on push­ing it for­ward in over­ex­pressed HER2 breast and gas­tric can­cers, as well as oth­er sol­id tu­mors. A prostate can­cer pro­gram will al­so see some funds.

The Bei­jing in­vest­ment firm HOPU stands to gain the most from this IPO, as it will own a 14.8% stake in Am­brx af­ter the of­fer­ing is fin­ished. WuXi is al­so in­volved with 11.1% of post-of­fer­ing shares. CEO Feng Tian will col­lect some cash as well, own­ing about 5.8 mil­lion shares that amount to a 2.2% stake.

Am­brx will trade un­der the tick­er $AMAM.





Source link

Related articles

World’s largest duty-free retailer aims for Hong Kong’s biggest IPO of year – South China Morning Post

August 10, 2022

NSW Police dumps Bezos-backed Mark43 from core systems overhaul – Strategy – Security

August 10, 2022

Related Posts

World’s largest duty-free retailer aims for Hong Kong’s biggest IPO of year – South China Morning Post

by MtR
August 10, 2022
0

World’s largest duty-free retailer aims for Hong Kong’s biggest IPO of year  South China Morning Post Source link

NSW Police dumps Bezos-backed Mark43 from core systems overhaul – Strategy – Security

by MtR
August 10, 2022
0

Plans to replace NSW’s core policing system with a new cloud-based crime-fighting platform are in disarray after NSW Police terminated...

Syrma share sale to offer cues for IPO fence-sitters

by MtR
August 9, 2022
0

MUMBAI : The primary market will offer important cues to IPO-bound companies and investors this week. After a dry patch...

AIG eyes September as next window for unit’s IPO

by MtR
August 9, 2022
0

AIG, one of the world's biggest commercial insurers, on Monday blamed market volatility for the delay, becoming the latest company...

Gov. AbdulRazaq mourns Chief Imam of Ajase-Ipo

by MtR
August 9, 2022
0

The Governor said the death of the Chief Imam was a depletion in the rank of community leaders whose leadership...

Load More
  • Trending
  • Comments
  • Latest

Bank of England tells ministers to intervene on digital currency ‘programming’

June 21, 2021

Tips for checking smoke alarms during daylight saving time

March 12, 2022

GLOBAL MARKETS-U.S. stocks follow Europe up; Treasury yields rise, dollar firm

July 9, 2021

What will Durham County education bonds pay for? A full list

July 8, 2022
African currencies week ahead: Zambia's kwacha seen on back foot, Kenyan shilling up – Business Recorder

African currencies week ahead: Zambia's kwacha seen on back foot, Kenyan shilling up – Business Recorder

0
Maxum Foods releases Global Dairy Commodity Update for June

Maxum Foods releases Global Dairy Commodity Update for June

0
Letter: Perpetual bonds can help states fight hunger

Letter: Perpetual bonds can help states fight hunger

0
United Kingdom ETFs Are Riding the Re-Opening Momentum

United Kingdom ETFs Are Riding the Re-Opening Momentum

0

Investment in overseas real estate surges : The DONG-A ILBO

August 11, 2022

U.S. inflation CPI report, Wall Street, currencies

August 10, 2022

Alberta oil production set new record in first half of 2022

August 10, 2022

Industrial Lubricants Market to Reach $71 Billion by 2027.

August 10, 2022

Recent News

Investment in overseas real estate surges : The DONG-A ILBO

August 11, 2022

U.S. inflation CPI report, Wall Street, currencies

August 10, 2022

Alberta oil production set new record in first half of 2022

August 10, 2022

Categories

  • Asia
  • Bonds
  • Canada
  • Commodities
  • Cryptocurrencies
  • Currencies
  • Emerging Markets
  • ETFs
  • Europe & Middle East
  • IPOs
  • Latin America
  • Mutual Funds
  • Personal Finance
  • Real Estate
  • Retirement
  • Spending & Saving
  • Stocks
  • U.S. Markets
  • Privacy & Policy
  • About Us
  • Contact Us
  • Advertise with us

© 2021 Copyright Market-Reporter

No Result
View All Result
  • Home
  • Markets
    • U.S. Markets
    • Canada
    • Europe & Middle East
    • Emerging Markets
    • Asia
    • Latin America
  • Investing
    • Stocks
    • IPOs
    • Mutual Funds
    • ETFs
    • Bonds
    • Commodities
    • Currencies
    • Cryptocurrencies
  • Economy & Politics
    • Personal Finance
    • Spending & Saving
    • Retirement
    • Real Estate

© 2021 Copyright Market-Reporter